{"id":22163,"date":"2025-02-04T11:03:58","date_gmt":"2025-02-04T11:03:58","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/limpatto-delle-killer-acquisitions-sullo-sviluppo-di-nuovi-farmaci\/"},"modified":"2025-02-12T17:05:13","modified_gmt":"2025-02-12T17:05:13","slug":"the-impact-of-killer-acquisitions-on-the-development-of-new-drugs","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/","title":{"rendered":"The impact of killer acquisitions on the development of new drugs"},"content":{"rendered":"

The pharmaceutical industry<\/strong> is characterized by a high level of investment in research and development (R&D)<\/strong>, aimed at discovering new treatments and innovative therapies. However, some market strategies can threaten innovation itself<\/strong>. Among these, the phenomenon of killer acquisitions<\/strong> is attracting increasing attention from antitrust authorities and industry experts.<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n

A killer acquisition occurs when a company acquires a potential competitor with the aim of interrupting the development of an innovative drug that could compete with its own products. This phenomenon is particularly harmful to scientific progress, as it reduces the variety of available therapeutic options and limits competition.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n

The methodology of the study<\/span><\/h2>\n<\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n

An analysis of more than 6,300 deals in the pharmaceutical sector between 2014 and 2018<\/strong> highlighted that approximately 240 deals had potential overlap in terms of therapeutic indications and mechanisms of action. Among these, 183 showed a subsequent interruption in the development of at least one of the drugs involved, while 92 presented elements that suggested the possibility of a killer acquisition.<\/span><\/p>\n

\n
\n
\n
\n
\n
\n

The study was based on a bottom-up analysis approach, using public data from authoritative sources such as clinicaltrials.gov and pharmaceutical transaction databases. The goal was to identify transactions in which a drug in development was discontinued without clear technical justification<\/strong>.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

Main Results
\nThe analysis revealed that:<\/span><\/h2>\n
    \n
  • \n

    38% of transactions with therapeutic overlaps led to disruptions in the development of at least one drug. <\/span><\/p>\n<\/li>\n

  • \n

    Killer acquisitions were most frequent in mergers and acquisitions (54% of suspected cases), followed by licensing agreements (27%) and asset purchases (33%). <\/span><\/p>\n<\/li>\n

  • \n

    Many of the discontinued projects involved drugs that were late in development and aimed at highly concentrated markets.<\/span><\/p>\n<\/li>\n<\/ul>\n

    \n
    \n
    \n
    \n
    \n
    \n

    A case in point is Johnson & Johnson’s acquisition of Actelion in 2017. The European Commission identified potential overlaps in insomnia treatments and imposed measures to avoid a discontinuation of the drug ACT-541468. However, development of competitor JNJ-7922 was later abandoned, raising questions about the effectiveness of the imposed remedies.<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

    Implications for the market and regulatory authorities<\/h3>\n
    \n
    \n
    \n
    \n
    \n
    \n

    Killer acquisitions introduce a complex challenge for competition authorities, as the reasons behind development disruptions can be difficult to prove. The analysis suggests that:<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

    \n
      \n
    1. Greater transparency<\/strong>: <\/span>Greater access to non-public data is needed to better assess the reasons for disruptions.<\/li>\n
    2. Post-acquisition monitoring:<\/strong> Authorities should actively monitor the evolution of acquired drugs, checking whether they are actually developed\n
      \n
      \n
      \n
      \n
      \n
      \n
      <\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n
    3. Reform of regulatory instruments:<\/strong> The current regulatory framework, based mainly on the analysis of mergers, may not be sufficient to intercept killer acquisitions that manifest themselves in the form of licensing agreements or R&D partnerships.\n
      \n
      \n
      \n
      \n
      \n
      \n
      <\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/li>\n<\/ol>\n

      Pharmaceutical innovation is a fundamental pillar of public health, but it must be protected from corporate strategies that undermine its progress. The study demonstrated that killer acquisitions represent a real threat to the sector and that current regulatory measures may not be sufficient to counter them.<\/p>\n<\/div>\n

      Competition authorities should adopt more effective tools to monitor the impact of acquisitions on pharmaceutical development and ensure that innovation is not sacrificed for market reasons. Only through more careful supervision will it be possible to ensure that acquisitions in the pharmaceutical sector promote scientific progress and not its suppression.<\/p>\n","protected":false},"excerpt":{"rendered":"

      Pharmaceutical innovation represents a crucial sector for public health, but acquisition strategies can sometimes compromise competition and market evolution. The phenomenon of “killer acquisitions” occurs when a company acquires a competitor not to develop its products, but to eliminate them, thus reducing potential competition. A recent study, through a large-scale bottom-up analysis, has highlighted the risks and implications of such strategies, suggesting a more rigorous approach by regulatory authorities.<\/p>\n","protected":false},"author":32,"featured_media":22109,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[796],"tags":[],"class_list":{"0":"post-22163","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-market"},"yoast_head":"\nThe impact of killer acquisitions on the development of new drugs - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Acquisition strategies can compromise competition and market evolution: a study has highlighted risks and implications\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The impact of killer acquisitions on the development of new drugs - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Acquisition strategies can compromise competition and market evolution: a study has highlighted risks and implications\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-04T11:03:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T17:05:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"headline\":\"The impact of killer acquisitions on the development of new drugs\",\"datePublished\":\"2025-02-04T11:03:58+00:00\",\"dateModified\":\"2025-02-12T17:05:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/\"},\"wordCount\":519,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg\",\"articleSection\":[\"Market\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/\",\"name\":\"The impact of killer acquisitions on the development of new drugs - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg\",\"datePublished\":\"2025-02-04T11:03:58+00:00\",\"dateModified\":\"2025-02-12T17:05:13+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"description\":\"Acquisition strategies can compromise competition and market evolution: a study has highlighted risks and implications\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg\",\"width\":2560,\"height\":1435,\"caption\":\"A capsule disperses advanced technology, epitomizing the new wave of precision medicine.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The impact of killer acquisitions on the development of new drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The impact of killer acquisitions on the development of new drugs - MakingPharmaIndustry","description":"Acquisition strategies can compromise competition and market evolution: a study has highlighted risks and implications","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/","og_locale":"en_US","og_type":"article","og_title":"The impact of killer acquisitions on the development of new drugs - MakingPharmaIndustry","og_description":"Acquisition strategies can compromise competition and market evolution: a study has highlighted risks and implications","og_url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2025-02-04T11:03:58+00:00","article_modified_time":"2025-02-12T17:05:13+00:00","og_image":[{"width":2560,"height":1435,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg","type":"image\/jpeg"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"headline":"The impact of killer acquisitions on the development of new drugs","datePublished":"2025-02-04T11:03:58+00:00","dateModified":"2025-02-12T17:05:13+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/"},"wordCount":519,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg","articleSection":["Market"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/","url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/","name":"The impact of killer acquisitions on the development of new drugs - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg","datePublished":"2025-02-04T11:03:58+00:00","dateModified":"2025-02-12T17:05:13+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"description":"Acquisition strategies can compromise competition and market evolution: a study has highlighted risks and implications","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/02\/AdobeStock_736940936-scaled.jpeg","width":2560,"height":1435,"caption":"A capsule disperses advanced technology, epitomizing the new wave of precision medicine."},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/market\/the-impact-of-killer-acquisitions-on-the-development-of-new-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"The impact of killer acquisitions on the development of new drugs"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/22163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=22163"}],"version-history":[{"count":2,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/22163\/revisions"}],"predecessor-version":[{"id":22166,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/22163\/revisions\/22166"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/22109"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=22163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=22163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=22163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}